These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25567366)

  • 1. Addressing the challenges of low clearance in drug research.
    Di L; Obach RS
    AAPS J; 2015 Mar; 17(2):352-7. PubMed ID: 25567366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in measurement of metabolic clearance, metabolite profile and reaction phenotyping of low clearance compounds.
    Di L
    Expert Opin Drug Discov; 2023; 18(11):1209-1219. PubMed ID: 37526497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery.
    Klopf W; Worboys P
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):159-69. PubMed ID: 20053167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
    Fontana S
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro-in vivo correlation for low-clearance compounds using hepatocyte relay method.
    Di L; Atkinson K; Orozco CC; Funk C; Zhang H; McDonald TS; Tan B; Lin J; Chang C; Obach RS
    Drug Metab Dispos; 2013 Dec; 41(12):2018-23. PubMed ID: 23857891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists.
    Hutzler JM; Ring BJ; Anderson SR
    Drug Metab Dispos; 2015 Dec; 43(12):1917-28. PubMed ID: 26363026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel relay method for determining low-clearance values.
    Di L; Trapa P; Obach RS; Atkinson K; Bi YA; Wolford AC; Tan B; McDonald TS; Lai Y; Tremaine LM
    Drug Metab Dispos; 2012 Sep; 40(9):1860-5. PubMed ID: 22645091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaction phenotyping to assess victim drug-drug interaction risks.
    Di L
    Expert Opin Drug Discov; 2017 Nov; 12(11):1105-1115. PubMed ID: 28820269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of LC-MS techniques and high-throughput approaches used to investigate drug metabolism by cytochrome P450s.
    Youdim KA; Saunders KC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(17-18):1326-36. PubMed ID: 20207203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of absolute quantitative (1)H NMR spectroscopy in drug discovery and development.
    Singh S; Roy R
    Expert Opin Drug Discov; 2016 Jul; 11(7):695-706. PubMed ID: 27187052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of major human excretory and circulating drug metabolites using a hepatocyte relay method.
    Ballard TE; Orozco CC; Obach RS
    Drug Metab Dispos; 2014 May; 42(5):899-902. PubMed ID: 24608634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design.
    Di L; Keefer C; Scott DO; Strelevitz TJ; Chang G; Bi YA; Lai Y; Duckworth J; Fenner K; Troutman MD; Obach RS
    Eur J Med Chem; 2012 Nov; 57():441-8. PubMed ID: 22840492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development.
    Di L; Feng B; Goosen TC; Lai Y; Steyn SJ; Varma MV; Obach RS
    Drug Metab Dispos; 2013 Dec; 41(12):1975-93. PubMed ID: 24065860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.
    Bell LC; Wang J
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1131-55. PubMed ID: 22681474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency in Drug Discovery: Liver S9 Fraction Assay As a Screen for Metabolic Stability.
    Richardson SJ; Bai A; Kulkarni AA; Moghaddam MF
    Drug Metab Lett; 2016; 10(2):83-90. PubMed ID: 26902079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic properties and in silico ADME modeling in drug discovery.
    Honório KM; Moda TL; Andricopulo AD
    Med Chem; 2013 Mar; 9(2):163-76. PubMed ID: 23016542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organotypic systems in drug metabolism and toxicity: challenges and opportunities.
    Dash A; Blackman BR; Wamhoff BR
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):999-1014. PubMed ID: 22632603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modeling and applications in drug discovery: challenges and recent advances.
    Yang SY
    Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.